Abiopharma

🔍 FUCHS ANNE SUTHERLAND (Director)

Company: GARTNER INC (IT)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 87 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: J | equity_swap_involved: 0 | shares_owned_after: 8,306.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: H | nature_of_ownership: 2024 GRAT | shares_owned_after: 4,644.00 | Footnotes: F2
• Acquired 87 shares of Common Stock Equivalent (CSE) (Derivative)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 29,664.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 87 shares of Common Stock Equivalent (CSE) (Derivative)
  Date: 2026-04-01 | Code: J | equity_swap_involved: 0 | shares_owned_after: 29,577.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: This reporting person has elected to receive an immediate distribution of the CSE shares.
• F2: These shares are held in a grantor retained annuity trust created on June 4, 2024 when the reporting person transferred 4,644 Gartner shares to the trust (the "2024 GRAT"). These shares are held in trust for the benefit of the reporting person and her children. The reporting person is the Trustee of the 2024 GRAT.
• F3: These are Common Stock Equivalents ("CSEs") received as compensation for service as an outside director of Gartner, Inc. They were granted under the Gartner, Inc. Long-Term Incentive Plan ("LTIP"). The CSEs convert into Gartner common stock on the date the outside director's continuous status as a director terminates, or as otherwise provided in the LTIP.